In this post-hoc analysis of a long-term safety study of rimegepant 75 mg in patients with migraine, the migraine-specific quality of life version 2.1 (MSQv2) survey was collected and mapped to EuroQol five-dimension (EQ-5D) utilities via a validated algorithm.

Patients were stratified into enrollment groups consisting of 52-week as-needed (PRN) rimegepant treatment for patients with 2–8 and 9–14 monthly migraine days (MMD), respectively, and 12-week PRN + every second day (QOD) treatment for patients with 4–14 MMD.

Over the course of follow-up, MSQv2 and mapped utilities improved across all enrollment groups.

Across enrollment groups, frequency of MMD decreased over the rimegepant treatment period, and descriptive associations were noted between lower MMD and better health-related quality of life (HRQoL), as characterized by MSQv2 and EQ-5D utility scores.

The analysis described here supports the relationship between reduction in migraine events and improved quality of life, and the impact of rimegepant (both PRN-only and QOD + PRN) on reducing frequency of MMD and increasing quality of life over time.